Report Gives Update on International API Inspections
A new report gives an overview of the work of the International API Inspection Program.
On April 12, 2018, the European Medicines Agency (EMA) announced the release of a report on the progress of the International API Inspection Program from 2011–2016. As part of the program, international regulators have collaborated to share information on good manufacturing (GMP) inspections of API manufacturers.
The program, which started as a pilot project in 2008, began in response to the growing outsourcing of APIs from international manufacturers. The objective of the program is to evaluate and coordinate inspections of the facilities of contract API manufacturers to ensure quality of the supply chain.
The report presents an overview of the activities by European authorities, the US Food and Drug Administration, Australia’s Therapeutic Goods Administration, and the World Health Organization between 2011 and 2016. During the six years covered in the report, 1333 inspections were performed at 458 manufacturing sites located in 18 different countries (49% in India and 36% in China).
The program is beneficial, authorities say, and it will continue. Plans to streamline the program and make improvements to the electronic information exchange platforms were proposed.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
